Impact of nebulized Tranexamic Acid in control of hemoptysis

Impact of administration of nebulized Tranexamic Acid in control of symptoms and outcome of patients with moderate and severe hemoptysis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170313033051N2

Enrollment

Registered

2019-03-30

Start date

2019-04-19

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoptysis. Hemoptysis

Interventions

Intervention 1: Intervention group: Nebulizing Tranexamic Acid 500 mg (5 cc) / q12 h for 4 times. Intervention 2: Control group: Nebulizing distilled water 5 cc / q12 h for 4 times.

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Moderate and severe hemoptysis Age above 15 years old

Exclusion criteria

Exclusion criteria: History of allergy to Tranexamic Acid Active thromboembolic event lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Volume of hemoptysis. Timepoint: first 48 h after admission. Method of measurement: Frequency and volume of hemoptysis (scaled container).	—

Secondary

Measure	Time frame
Need to invasive interventions and hospital length of stay. Timepoint: first 48 h after admission. Method of measurement: Questionnaire and hospital documents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Afzalimoghaddam

Tehran University of Medical Sciences

afzalimoghadam@tums.ac.ir+98 21 6690 4848

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026